![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: KIAA1614 |
Gene summary for KIAA1614 |
![]() |
Gene information | Species | Human | Gene symbol | KIAA1614 | Gene ID | 57710 |
Gene name | KIAA1614 | |
Gene Alias | KIAA1614 | |
Cytomap | 1q25.3 | |
Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | Q5VZ46 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
57710 | KIAA1614 | HCC1 | Human | Liver | HCC | 2.66e-20 | 1.68e+00 | 0.5336 |
57710 | KIAA1614 | HCC2 | Human | Liver | HCC | 2.52e-33 | 1.99e+00 | 0.5341 |
57710 | KIAA1614 | HCC5 | Human | Liver | HCC | 1.79e-32 | 1.66e+00 | 0.4932 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000716322 | Liver | HCC | establishment or maintenance of cell polarity | 133/7958 | 218/18723 | 2.48e-08 | 5.73e-07 | 133 |
GO:0031023 | Liver | HCC | microtubule organizing center organization | 82/7958 | 143/18723 | 2.38e-04 | 1.79e-03 | 82 |
GO:0007098 | Liver | HCC | centrosome cycle | 75/7958 | 130/18723 | 3.33e-04 | 2.34e-03 | 75 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
KIAA1614 | SNV | Missense_Mutation | novel | c.1990N>C | p.Glu664Gln | p.E664Q | Q5VZ46 | protein_coding | deleterious(0.01) | benign(0.407) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
KIAA1614 | SNV | Missense_Mutation | c.3172C>T | p.His1058Tyr | p.H1058Y | Q5VZ46 | protein_coding | tolerated(0.53) | possibly_damaging(0.857) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
KIAA1614 | SNV | Missense_Mutation | novel | c.1933N>T | p.Pro645Ser | p.P645S | Q5VZ46 | protein_coding | tolerated(0.08) | benign(0.441) | TCGA-AC-A6IW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
KIAA1614 | SNV | Missense_Mutation | c.2426N>A | p.Thr809Asn | p.T809N | Q5VZ46 | protein_coding | deleterious(0) | possibly_damaging(0.893) | TCGA-AO-A0JD-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | |
KIAA1614 | SNV | Missense_Mutation | rs760919913 | c.3433N>A | p.Gly1145Ser | p.G1145S | Q5VZ46 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
KIAA1614 | SNV | Missense_Mutation | c.127C>G | p.Gln43Glu | p.Q43E | Q5VZ46 | protein_coding | deleterious(0.01) | possibly_damaging(0.78) | TCGA-BH-A0BZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | CR | |
KIAA1614 | SNV | Missense_Mutation | c.1846N>A | p.Asp616Asn | p.D616N | Q5VZ46 | protein_coding | tolerated(0.06) | probably_damaging(0.947) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
KIAA1614 | SNV | Missense_Mutation | novel | c.2137N>A | p.Glu713Lys | p.E713K | Q5VZ46 | protein_coding | deleterious(0.01) | benign(0.402) | TCGA-D8-A73U-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
KIAA1614 | SNV | Missense_Mutation | rs753789554 | c.571G>A | p.Glu191Lys | p.E191K | Q5VZ46 | protein_coding | deleterious(0.02) | benign(0.073) | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
KIAA1614 | SNV | Missense_Mutation | rs375225309 | c.2530N>T | p.Arg844Trp | p.R844W | Q5VZ46 | protein_coding | deleterious(0.05) | benign(0.237) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |